All In Biotech

Drug Trial Radar · NCT05492500

A Study of Ponsegromab in People With Heart Failure

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 455 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

455

Actual

Start

Sep 26, 2022

Primary completion

Mar 5, 2025

Study completion Mar 5, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
The TIMI Study Group
First posted
Aug 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that looks like the study medicine but does not contain the active medicine) for treatment of symptoms related to heart failure. Participants will not know which treatment group they are assigned to. Most participants in this study will receive the study medicine or placebo by shots under the skin every four weeks. People may be able to participate in this study if they have heart failure. Participants will take part in this study for about 9 months. During this time participants will visit the study clinic once a month. A separate PK cohort within this clinical trial will receive open-label study medicine (Ponsegromab/PF-06946860) only. Participants in this open-label, PK cohort will not receive placebo. These participants will receive the study medicine by shots under the skin every four weeks. People may be able to participate in this study cohort if they also have heart failure. Participants will take part in the open-label, PK cohort for about 7 months.

Conditions

  • Heart Failure

Interventions

  • Main cohort (Cohort A): Ponsegromab low doseDrug

    Ponsegromab low dose subcutaneous injection

  • Main cohort (Cohort A): Ponsegromab medium doseDrug

    Ponsegromab medium dose subcutaneous injection

  • Main cohort (Cohort A): ponsegromab high doseDrug

    Ponsegromab high dose subcutaneous injection

  • Main cohort (Cohort A): Matched placeboOther

    Matched placebo subcutaneous injection

  • Open-label, PK Cohort (Cohort B): ponsegromab low doseDrug

    ponsegromab low dose subcutaneous injection

  • Open-label, PK Cohort (Cohort B): ponsegromab medium doseDrug

    Ponsegromab medium dose subcutaneous injection

  • Open-label, PK Cohort (Cohort B): ponsegromab high doseDrug

    Ponsegromab high dose subcutaneous injection

  • Optional Cohort C: Ponsegromab low doseDrug

    Ponsegromab low dose subcutaneous injection

  • Optional Cohort C: Matched placeboOther

    Matched placebo subcutaneous injection

  • Optional Cohort D: Ponsegromab high doseDrug

    Ponsegromab high dose subcutaneous injection

  • Optional Cohort D: Matched placeboOther

    Matched placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 - Clinical Summary Score (CSS) at Week 22: Cohort A, Ponsegromab 300 mg Versus PlaceboTime frame: Baseline [the last measurement on study Day 1], Week 22

Locations

122 sites in 11 countries. Site status is shown where the registry gives one.

  • Eastern shore Research Institute LLC

    Fairhope, Alabama

  • Keck Medical Center of USC

    Los Angeles, California

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Emory University School of Medicine-Grady Campus

    Atlanta, Georgia

  • Chicago Medical Research

    Hazel Crest, Illinois

  • Reid Physician Associates

    Richmond, Indiana

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Traverse Heart & Vascular

    Traverse City, Michigan

  • M Health Fairview Clinics and Surgery Center

    Minneapolis, Minnesota

  • M Health Fairview University of Minnesota Investigational Drug Services

    Minneapolis, Minnesota

  • M Health Fairview University of Minnesota Medical Center-East Bank

    Minneapolis, Minnesota

  • University of Minnesota/Lillehei Clinical Research Unit

    Minneapolis, Minnesota

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri

  • Washington University in St. Louis Center for Outpatient Health (COH)

    St Louis, Missouri

  • Washington University in St. Louis Center for Advanced Medicine (CAM)

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Holy Name Medical Center

    Teaneck, New Jersey

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Clinical and Translational Research Center

    Chapel Hill, North Carolina

  • South Oklahoma Heart Research, LLC

    Oklahoma City, Oklahoma

  • Texas Health Heart & Vascular Specialist (THHVS) #18760

    Dallas, Texas

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Core Research Group

    Brisbane, Queensland, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Fraser Clinical Trials Inc

    New Westminster, British Columbia, Canada

  • QEII Health Sciences Centre - Victoria General Site

    Halifax, Nova Scotia, Canada

  • Saul Vizel Professional Medicine Corporation dba Vizel Cardiac Research

    Cambridge, Ontario, Canada

  • University Hospital - London Health Sciences Centre

    London, Ontario, Canada

  • North York Diagnostic and Cardiac Centre

    North York, Ontario, Canada

  • Private Practice - Dr. James Cha

    Oshawa, Ontario, Canada

  • Kawartha Cardiology Clinical Trials

    Peterborough, Ontario, Canada

  • Corcare

    Toronto, Ontario, Canada

  • Unity Health Toronto, St. Michael's Hospital

    Toronto, Ontario, Canada

  • Community Care Building

    Winchester, Ontario, Canada

  • Winchester District Memorial Hospital

    Winchester, Ontario, Canada

  • Institut de Cardiologie de Montreal

    Montreal, Quebec, Canada

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.